Show simple item record

dc.contributor.authorRanjan, Sanjeev
dc.contributor.authorBosch, Stef
dc.contributor.authorLukkari, Hannamari
dc.contributor.authorSchirmer, Johanna
dc.contributor.authorAaltonen, Niina
dc.contributor.authorNieminen, Heikki J.
dc.contributor.authorLehto, Vesa-Pekka
dc.contributor.authorUrtti, Arto
dc.contributor.authorLajunen, Tatu
dc.contributor.authorRilla, Kirsi
dc.date.accessioned2024-08-28T11:56:07Z
dc.date.available2024-08-28T11:56:07Z
dc.date.issued2024
dc.identifier.citationRanjan, S., Bosch, S., Lukkari, H., Schirmer, J., Aaltonen, N., Nieminen, H. J., Lehto, V.-P., Urtti, A., Lajunen, T., & Rilla, K. (2024). Development of Focused Ultrasound-Assisted Nanoplexes for RNA Delivery. <i>Nanomaterials</i>, <i>14</i>(13), Article 1089. <a href="https://doi.org/10.3390/nano14131089" target="_blank">https://doi.org/10.3390/nano14131089</a>
dc.identifier.otherCONVID_220852618
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/96808
dc.description.abstractRNA-based therapeutics, including siRNA, have obtained recognition in recent years due to their potential to treat various chronic and rare diseases. However, there are still limitations to lipid-based drug delivery systems in the clinical use of RNA therapeutics due to the need for optimization in the design and the preparation process. In this study, we propose adaptive focused ultrasound (AFU) as a drug loading technique to protect RNA from degradation by encapsulating small RNA in nanoliposomes, which we term nanoplexes. The AFU method is non-invasive and isothermal, as nanoplexes are produced without direct contact with any external materials while maintaining precise temperature control according to the desired settings. The controllability of sample treatments can be effectively modulated, allowing for a wide range of ultrasound intensities to be applied. Importantly, the absence of co-solvents in the process eliminates the need for additional substances, thereby minimizing the potential for cross-contaminations. Since AFU is a non-invasive method, the entire process can be conducted under sterile conditions. A minimal volume (300 μL) is required for this process, and the treatment is speedy (10 min in this study). Our in vitro experiments with silencer CD44 siRNA, which performs as a model therapeutic drug in different mammalian cell lines, showed encouraging results (knockdown > 80%). To quantify gene silencing efficacy, we employed quantitative polymerase chain reaction (qPCR). Additionally, cryo-electron microscopy (cryo-EM) and atomic force microscopy (AFM) techniques were employed to capture images of nanoplexes. These images revealed the presence of individual nanoparticles measuring approximately 100–200 nm in contrast with the random distribution of clustered complexes observed in ultrasound-untreated samples of liposome nanoparticles and siRNA. AFU holds great potential as a standardized liposome processing and loading method because its process is fast, sterile, and does not require additional solvents.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesNanomaterials
dc.rightsCC BY 4.0
dc.subject.otherfocused ultrasound
dc.subject.othernanoplexes
dc.subject.othersiRNA delivery
dc.subject.otherphospholipid bilayer fragments
dc.subject.otherencapsulation efficiency
dc.subject.otherlipid nanoparticles
dc.titleDevelopment of Focused Ultrasound-Assisted Nanoplexes for RNA Delivery
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202408285693
dc.contributor.laitosKemian laitosfi
dc.contributor.laitosDepartment of Chemistryen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn2079-4991
dc.relation.numberinseries13
dc.relation.volume14
dc.type.versionpublishedVersion
dc.rights.copyright© 2024 the Authors
dc.rights.accesslevelopenAccessfi
dc.subject.ysoRNA
dc.subject.ysonanohiukkaset
dc.subject.ysoliposomit
dc.subject.ysonanobiotekniikka
dc.subject.ysonanotekniikka
dc.subject.ysonanolääketiede
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p7689
jyx.subject.urihttp://www.yso.fi/onto/yso/p23451
jyx.subject.urihttp://www.yso.fi/onto/yso/p38725
jyx.subject.urihttp://www.yso.fi/onto/yso/p27775
jyx.subject.urihttp://www.yso.fi/onto/yso/p11463
jyx.subject.urihttp://www.yso.fi/onto/yso/p28422
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.3390/nano14131089
jyx.fundinginformationThis research work was financially supported by Jane and Aatos Erkko Foundation and The Academy of Finland GeneCellNano Flagship (#337120).
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY 4.0
Except where otherwise noted, this item's license is described as CC BY 4.0